Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.
Inclusion Criteria: * Patients ≥ 18 years-old at time of consent. * Diagnosis: hematologic malignancy in morphologic remission who will be treated with RI or NMA conditioning and GVHD prophylaxis CNI-based (CNI without PTCY) plus abatacept or PTCY-based (CNI with PTCY). * Recipients of 7-8/8 related or unrelated HLA-matched or related haploidentical donor. * Peripheral blood stem cell graft * Allo-HCT day \<120 at time of consent Post-HCT inclusion criteria (within 3 weeks before start of belumosudil treatment) * Patient has received an allo-HCT transplant and is in morphologic remission (b…
Belumosudil is an oral selective inhibitor of Rho-GTPase-associated coiled-coil kinase 2 (ROCK2)